Clinical Edge Journal Scan

Migraine Not Linked to Atrial Fibrillation Risk


 

Key clinical point: Migraine, migraine with aura (MA), and migraine without aura (MO) were not associated with a higher risk for atrial fibrillation (AF), with migraine and its subtypes serving as a protective factor for AF in individuals age ≥ 55 years with migraine.

Major finding: No significant association was found between migraine (adjusted hazard ratio [aHR] 0.76; 95% CI 0.48-1.18), MA (aHR 1.00; 95% CI 0.59-1.70), or MO (aHR 0.50; 95% CI 0.23-1.06) and the risk for AF. However, among patients age ≥ 55 years, the risk for AF was significantly lower in those with migraine (aHR 0.53; 95% CI 0.39-0.73), MA (aHR 0.58; 95% CI 0.38-0.87), or MO (aHR 0.48; 95% CI 0.30-0.78) than in those without headache.

Study details: This prospective, population-based 9-year follow-up study included 39,340 individuals (age 20 years) without AF who answered the headache questionnaire during the Trøndelag Health Study; of these, 1524 (3.8%) developed AF.

Disclosures: This study did not receive any specific funding from any sources. The authors declared no conflicts of interest.

Source: Giri S, Tronvik E, Dalen H, et al. Migraine and risk of atrial fibrillation: A 9-year follow-up based on the Trøndelag Health Study. Cephalalgia. 2024 (May 29). doi: 10.1177/03331024241254517 Source

Recommended Reading

Diphenhydramine and Prochlorperazine Combo Not Associated With Migraine Treatment Failure
Migraine ICYMI
Migraine Disability Nearly Doubled in US Between 2005 and 2018
Migraine ICYMI
Commentary: Looking at Migraine Treatment in a Comprehensive Way, June 2024
Migraine ICYMI
Interictal Burden, Disability, Allodynia Linked to Increased Likelihood of Seeking Migraine Care
Migraine ICYMI
Measuring Cognition in Migraine, One Patient at a Time
Migraine ICYMI
Prior Non-response to Anti-CGRP mAb Curbs Efficacy of Eptinezumab
Migraine ICYMI
Healthy Lifestyle and Good Cardiovascular Health Can Ward Off Migraine
Migraine ICYMI
Rimegepant Reduces Need for Analgesics and Antiemetics in Adults With Migraine
Migraine ICYMI
Atogepant Shows Sustained Efficacy in Episodic Migraine
Migraine ICYMI
Predictors for Anti-CGRP mAb Response in Migraine
Migraine ICYMI